Veterinary Research Communications

, Volume 42, Issue 1, pp 49–56 | Cite as

R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes

  • Shota Kawakami
  • Kazuhiko OchiaiEmail author
  • Daigo Azakami
  • Yuiko Kato
  • Masaki Michishita
  • Masami Morimatsu
  • Toshina Ishiguro-Oonuma
  • Eri Onozawa
  • Masami Watanabe
  • Toshinori Omi
Original Article


Glioma is the second most common intracranial neoplasia in dogs, but the pathogenic mechanisms remain unclear. In humans, isocitrate dehydrogenase 1 (IDH1) is frequently mutated in gliomas. Although almost all human IDH1 mutations have been identified as involving the Arg132 codon, few studies have reported structural, functional, and mutational information for canine IDH1. Therefore, in this study, we cloned the canine IDH1 homologue and used PCR mutagenesis to substitute the wildtype (WT) Arg132 with His (R132H) or Ser (R132S). WT and mutated IDH1 were overexpressed in HeLa cells, and their presence was confirmed by immunoblotting and immunocytochemistry using mutation-specific antibodies. The IDH1 activity between WT, R132H, and R132S transfectants was compared by measuring the production of NADH and NADPH. NADPH production in R132H and R132S transfectants was lower than that in WT, but NADH levels were not significantly different. Finally, we detected increased expression of hypoxia inducible factor 1 alpha (HIF-1α) in the R132H and R132S transfectants. These results indicated that the canine IDH1 Arg132 mutation has the potential to induce carcinogenesis in canine somatic cells.


Canine Glioma Isocitrate dehydrogenase 1 Mutation 



This work was supported by KAKENHI scientific research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 15K07754).

Compliance with ethical standards

Conflict of interest

Authors declare that they have no conflict of interest.

Informed consent

This manuscript does not contain any studies with human subjects performed by any of the authors.

Human and animal rights

All experiments were executed according to the Guide for the Care and Use of Laboratory Animals and approved by the institutional animal ethics committee.


  1. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchtti A, Bardelli A (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7–11CrossRefPubMedGoogle Scholar
  2. Capper D, Zentgraf H, Balss J, Hartmann C, Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601CrossRefPubMedGoogle Scholar
  3. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Heiden MGV, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744CrossRefPubMedPubMedCentralGoogle Scholar
  4. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL (2002) Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 43:240–246CrossRefPubMedGoogle Scholar
  5. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567CrossRefPubMedPubMedCentralGoogle Scholar
  6. Frezza C, Tennant DA, Gottlieb E (2010) IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 17:7–9CrossRefPubMedGoogle Scholar
  7. Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y (2015) A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Biochem Biophys Res Commun 466:733–739CrossRefPubMedGoogle Scholar
  8. Geisbrecht BV, Gould SJ (1999) The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 274:30527–30533CrossRefPubMedGoogle Scholar
  9. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344CrossRefPubMedPubMedCentralGoogle Scholar
  10. Jennings GT, Sechi S, Stevenson PM, Tuckey RC, Parmelee D, McAlister-Henn L (1994) Cytosolic NADP(+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J Biol Chem 269:23128–23134PubMedGoogle Scholar
  11. Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 406:608–613CrossRefPubMedGoogle Scholar
  12. Kaneko MK, Ogasawara S, Kato Y (2013) Establishment of a novel multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med 230:103–109CrossRefGoogle Scholar
  13. Kato Y (2015) Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol 32:3–11CrossRefPubMedGoogle Scholar
  14. Lu C, Thompson CB (2012) Metabolic regulation of epigenetics. Cell Metab 16:9–17CrossRefPubMedPubMedCentralGoogle Scholar
  15. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058–1066CrossRefPubMedPubMedCentralGoogle Scholar
  16. Nekrutenko A, Hillis DM, Patton JC, Bradley RD, Baker RJ (1998) Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol Biol Evol 15:1674–1684CrossRefPubMedGoogle Scholar
  17. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRefPubMedPubMedCentralGoogle Scholar
  18. Peterson JD (2017) Short-nosed dogs unexpected partners for brain cancer researchers. The Jackson laboratory, The news and insight Accessed 13 November 2017
  19. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932–941CrossRefPubMedPubMedCentralGoogle Scholar
  20. Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLedonn RE, Yan H (2010) IDH1 and IDH2 hotspot mutations are not found in canine glioma. Int J Cancer 127:245–246CrossRefPubMedPubMedCentralGoogle Scholar
  21. Rydstrom J (2006) Mitochondrial NADPH, transhydrogenase and disease. Biochim Biophys Acta 1757:721–726CrossRefPubMedGoogle Scholar
  22. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 116:5486–5496CrossRefPubMedGoogle Scholar
  23. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Learry RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JKV, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274CrossRefPubMedGoogle Scholar
  24. Struys EA, Salomons GS, Achouri Y, Van Schaftingen E, Grosso S, Craigen WJ, Verhoeven NM, Jakobs C (2005) Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet 76:358–360CrossRefPubMedGoogle Scholar
  25. Takano S, Kato Y, Yamamoto T, Liu X, Ishikawa E, Kaneko MK, Ogasawara S, Matsuda M, Noguchi M, Matsumura A (2015) Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas. Brain Tumor Pathol 32:169–175CrossRefPubMedGoogle Scholar
  26. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483CrossRefPubMedPubMedCentralGoogle Scholar
  27. van Lith SA, Navis AC, Lenting K, Verrijp K, Schepens JT, Hendriks WJ, Scubert NA, Venselaar H, Wevers RA, van Rooij A, Wesseling P, Molenaar RJ, van Noorden CJ, Pusch S, Tops B, Leenders WP (2016) Identification of a novel inactivating mutation in isocitrate dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. Sci Rep 6:30486CrossRefPubMedPubMedCentralGoogle Scholar
  28. Wajner M, Latini A, Wyse AT, Dutra-Filho CS (2004) The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis 27:427–448CrossRefPubMedGoogle Scholar
  29. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30CrossRefPubMedPubMedCentralGoogle Scholar
  30. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Binger DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedPubMedCentralGoogle Scholar
  31. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lie Q, Guan KL, Xiong Y (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261–265CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2017

Authors and Affiliations

  • Shota Kawakami
    • 1
  • Kazuhiko Ochiai
    • 1
    Email author
  • Daigo Azakami
    • 1
  • Yuiko Kato
    • 1
  • Masaki Michishita
    • 2
  • Masami Morimatsu
    • 3
  • Toshina Ishiguro-Oonuma
    • 4
  • Eri Onozawa
    • 1
  • Masami Watanabe
    • 5
  • Toshinori Omi
    • 1
  1. 1.School of Veterinary Nursing and Technology, Faculty of Veterinary ScienceNippon Veterinary and Life Science UniversityTokyoJapan
  2. 2.Department of Veterinary Pathology, Faculty of Veterinary ScienceNippon Veterinary and Life Science UniversityTokyoJapan
  3. 3.Laboratory of Laboratory Animal Science and Medicine, Department of Disease Control, Graduate School of Veterinary MedicineHokkaido UniversitySapporoJapan
  4. 4.Laboratory of Veterinary Physiology, Cooperative Department of Veterinary Medicine, Faculty of AgricultureIwate UniversityMoriokaJapan
  5. 5.Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayama UniversityOkayamaJapan

Personalised recommendations